Mohan Srinivasan
67Patents
19h-index
109Co-inventors
83Inventor score
Filing activity: May 22, 2003 → May 13, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8008449B2 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics | Emerging Cross-Sectional Technologies | 812 | Active |
| US7943743B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 541 | Active |
| US8779105B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 204 | Active |
| US8383796B2 | Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 148 | Active |
| US9084776B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 134 | Active |
| US9492540B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 116 | Active |
| US9358289B2 | Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies | Emerging Cross-Sectional Technologies | 112 | Active |
| US9387247B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 98 | Active |
| US9492539B2 | Monoclonal antibodies to Programmed Death 1 (PD-1) | Emerging Cross-Sectional Technologies | 96 | Active |
| US9102725B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 90 | Active |
| US9273135B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 77 | Active |
| US7456264B2 | Human monoclonal antibodies against Bacillus anthracis protective antigen | Chemistry; Metallurgy | 70 | Expired |
| US7217796B2 | Neutralizing human anti-IGFR antibody | Chemistry; Metallurgy | 60 | Expired |
| US9505839B2 | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof | Chemistry; Metallurgy | 49 | Active |
| US9580507B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 47 | Active |
| US9580505B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 31 | Active |
| US9228016B2 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | Physics | 31 | Active |
| US10441655B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 21 | Active |
| US9605080B2 | Antibodies against CD73 | Physics | 19 | Active |
| US10189902B2 | Antibodies to TIGIT | Emerging Cross-Sectional Technologies | 19 | Active |
| US10266591B2 | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof | Chemistry; Metallurgy | 14 | Active |
| US10377824B2 | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof | Chemistry; Metallurgy | 13 | Active |
| US10100129B2 | Antibodies against CD73 and uses thereof | Physics | 13 | Active |
| US8496931B2 | Monoclonal antibodies against stromal derived factor-1 (SDF-1) | Chemistry; Metallurgy | 12 | Active |
| US9745379B2 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | Physics | 11 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.